林璐;曾英彤;陈文颖;蔡淦禧;周婧;劳海燕;杨敏;
LIN Lu;ZENG Yingtong;CHEN Wenying;CAI Ganxi;ZHOU Jing;LAO Haiyan;YANG Min;Department of Pharmacy,Guangdong Provincal People's Hospital,Guangdong Academy of Medical Sciences;Guangdong Pharmaceutical University;Guangdong Provincial Cardiovascular Research Institute;

• 1:广东省人民医院广东省医学科学院药学部
• 2:广东药科大学
• 3:广东省心血管病研究所

摘要(Abstract)：

目的了解某院心脏手术患者围手术期盐酸氨溴索注射剂不同给药途径的用药情况,为临床合理使用该药提供参考。方法纳入行心脏手术的心外科患者,使用盐酸氨溴索注射剂的作为试验组,并按给药途径分为静脉组、雾化组和静脉联合雾化组(简称"联合组");未使用盐酸氨溴索注射剂的作为对照组。对比不同给药途径组患者术后肺部并发症(postoperative pulmonary complications,PPCs)的发生率、重插管发生率、总呼吸机使用时间、纤支镜吸痰率、好转率、ICU停留时间和总住院时间。结果共纳入916例患者,其中静脉组180例、雾化组104例、联合组524例、对照组108例。PPCs在心脏手术术后的总发生率为94. 2%,不同给药途径组的PPCs发生率(P=0. 977)无统计学差异;呼吸机使用时间仅对照组与联合组存在统计学差异(P<0. 001),其他组之间无统计学差异(P>0. 008);重插管率除雾化组无重插管病例,与其他各组的差异有统计学意义外,静脉组(6. 0%)、联合组(6. 1%)和对照组(11. 1%)之间无统计学差异(P>0. 008)。不同给药途径组的愈后好转率(P=0.320)无统计学差异;对于ICU停留时间,静脉组、雾化组和联合组的时间较对照组长,差异有统计学意义(P<0. 001),其他各组间的差异无统计学意义(P>0. 008);对于纤支镜吸痰率,雾化组(0. 0%)<对照组(0. 9%)<静脉组(4. 4%)<联合组(7.6%);对于总住院时间(P<0. 001),中位住院天数对照组(15 d)<静脉组(19 d)<雾化组(21 d)≈联合组(21 d)。结论不同给药途径的盐酸氨溴索注射剂对患者的术后临床结局影响无明显差异,需设计前瞻性试验进一步验证。
OBJECTIVE To investigate the situation of ambroxol hydrochloride injection by different administration routes in the perioperative period among patients undergoing cardiac surgery in Guangdong General Hospital,so as to provide references for the rational use of ambroxol injection. METHODS Patients who underwent cardiac surgery and used ambroxol hydrochloride injection were in the experimental group,and the experimental group was further divided into three groups,intravenous,atomization,and intravenous combined atomization (the "combined group ") according to the routes of administration. Patients not injected with ambroxol hydrochloride were considered as a blank control group. Incidence of postoperative pulmonary complications (PPCs) after cardiac surgery,incidence of reintubation,time of mechanical ventilation,incidence of fiberbronchoscope suction,improvement rate,time stay in ICU,and time stay in hospital among the groups were compared. RESULTS A total of 916 patients were a included,of which the injection group contained 108 cases,inhalation group 104 cases,combination group 524 cases,and control group 108 cases. The incidence of PPCs was 94. 2%. No significant differences (P = 0. 977) were found in the incidences of PPCs among groups. Time of mechanical ventilation was statistically different between combination group and control group only (P < 0. 001) and there was no significant difference among experimental groups (P > 0. 008). Except inhalation group had no case for reintubation,incidences of reintubation were not significantly different (P > 0. 008) between injection group (6. 0%),combination group (6. 1%) and control group (11. 1%). Improvement rate was not significantly different among experimental groups (P = 0. 320);. Time stay in ICU,injection group,inhalation group,and combination group were longer than that in control group and significantly different (P<0. 001)compared with that in control group. However,there was no significant difference between other groups (P>0. 008). The combination group has the greatest incidence of fiberbronchoscope suction (7. 6%),followed by that in injection group (4. 4%),control group (0.9%),and inhalation group (0. 0%). Control group has the shortest time stay in hospital (15 d),followed by injection group (19 d),inhalation group (21 d),combination group (21 d). CONCLUSION The prognosis of patients for cardiac surgery has no significant difference among the groups with ambroxol hydrochloride injection by different administration routes in the perioperative period. Further well-designed prospective studies should be conducted for validation.

关键词(KeyWords)： 氨溴索;给药途径;心脏手术;围术期;临床应用
ambroxol;administration route;perioperative period;cardiac surgery;clinical application

Abstract:

Keywords:

基金项目(Foundation): 广州市科技计划项目(201509010012)

作者(Author): 林璐;曾英彤;陈文颖;蔡淦禧;周婧;劳海燕;杨敏;
LIN Lu;ZENG Yingtong;CHEN Wenying;CAI Ganxi;ZHOU Jing;LAO Haiyan;YANG Min;Department of Pharmacy,Guangdong Provincal People's Hospital,Guangdong Academy of Medical Sciences;Guangdong Pharmaceutical University;Guangdong Provincial Cardiovascular Research Institute;

Email:

DOI:

参考文献(References)：

• [1]邓勇志，孙宗全，Hugh S P．心脏外科术后肺部并发症危险因素分析[J]．临床心血管病杂志，2007,23(8):579-582．
• [2]Schuller D,Morrow L E.Pulmonary complications after coronary revascularization[J].Curr Opin Cardiol,2000,15(5):309-315．
• [3]中国医师协会胸外科医师分会．胸外科围手术期肺部并发症防治专家共识[J]．中华胸心血管外科杂志，2009,25(4):217-218．
• [4]王天佑．胸外科围手术期肺保护的专家共识[J]．中华外科杂志，2009,47(18):1361-1364．
• [5]周婧，陈文颖，劳海燕，等．广东省人民医院2012年住院患者盐酸氨溴索注射剂超说明书用药情况调查[J]．中国循证医学杂志，2014,14(9):1030-1037．
• [6]Smetana G W,Lawrence V A,Cornell J E.Preoperative pulmonary risk stratification for noncardiothoracic surgery:systematic review for the American College of Physicians[J].Ann Intern Med,2006,144(8):581-595．
• [7]叶红雨，梁毅，姜海明．盐酸氨溴索在老年人胸部手术围术期的肺保护作用[J]．中华老年医学杂志，2012,31(6):498-499．
• [8]雷光萍，陈汝婷．盐酸氨溴索不同给药途径对慢性阻塞性肺疾病急性加重期疗效的影响[J]．临床合理用药杂志，2016,9(24):40-41．
• [9]Ben Y,Chen J,Zhu R,et al.Upregulation of AQP3 and AQP5 induced by dexamethasone and ambroxol in A549 cells[J].Respiratory Physiology&Neurobiology,2008,161(2):111-118．
• [10]Chander S.Cell-specific modulation of surfactant proteins by ambroxol treatment[J].Toxicology&Applied Pharmacology,2005,203(1):27．
• [11]Fegiz G.Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery:double-blind Italian multicenter clinical study versus placebo[J].Lung,1991,169(2):69-76．
• [12]李海东，王志成，刘国祥．氨溴索对内毒素诱导急性肺损伤大鼠肺组织表面活性物质相关蛋白A表达影响[J]．西南军医，2006,8(1):32-34．
• [13]张国清，周新．氨溴索对炎症大鼠肺内炎性细胞聚集的影响[J]．中国呼吸与危重监护杂志，2005,4(3):197-239．
• [14]Wang S,Huang D,Ma Q,et al.Does ambroxol confer a protective effect on the lungs in patients undergoing cardiac surgery or having lung resection?[J].Interact Cardiovasc&Thorac Surg,2014,18(6):830-834．
• [15]Wang X,Wang L,Wang H Y,et al.Perioperative Lung Protection Provided by High-Dose Ambroxol in Patients with Lung Cancer[J].Cell Biochemistry and Biophysics,2015,73(2):281-284．
• [16]中华医学会呼吸病学分会专家组．雾化吸入疗法在呼吸疾病中的应用专家共识[J]．中华医学杂志，2016,96(34):2696-2708．
• [17]Zhang S J,Jiang J X,Ren Q Q,et al.Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1/2 signaling pathway[J].Eur J Pharmacol,2016,775(1):138-148．
• [18]Ren Y C,Wang L,He H B,et al.Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat[J].Journal of Pharmaceutical Sciences,2009,98(5):1797-1803．
• [19]Brueckl C,Kaestle S,Kerem A,et al.Hyperoxia-induced reactive oxygen species formation in pulmonary capillary endothelial cells in situ[J].Am J Respir Cell Mol Biol,2006,34(4):453-463．
• [20]Sablotzki A,Starzmann W,Scheubel R,et al.Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates[J].Can J Anaesth,2005,52(10):1076-1082．
• [21]Howarth P H.Why particle size should affect clinical response to inhaled therapy[J].J Aerosol Med,2001,14(1):S27-S34．
• [22]Heijerman H,Westerman E,Conway S,et al.Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis:A European consensus[J].J Cyst Fibros,2009,8(5):295-315．
• [23]雷光萍，陈汝婷．盐酸氨溴索不同给药途径对慢性阻塞性肺疾病急性加重期疗效的影响[J]．临床合理用药杂志，2016,9(24):40-41．
• [24]杨伟钦，许德超，白丽燕．氨溴索不同给药途径佐治婴幼儿肺炎的疗效比较[J]．儿科药学杂志，2005,11(1):31-32．
• [25]卢海崧，张伟华，刘亚民．盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病急性加重期的临床分析[J]．中外医疗，2009,28(22):1-2．
• [26]金艳，王蕾，赵璧君，等．沐舒坦不同给药途径对体外循环心脏手术患者肺保护效果的对照研究[J]．当代医学，2012,18(7):11-13．
• [27]王明丽，谢陶吟，许建平．注射用氨溴索雾化吸入致呼吸困难1例分析[J]．中国药房，2011,22(40):3791-3792．
• [28]黄元，李泮海，田月洁．40例盐酸氨溴索注射剂致严重不良反应/事件分析[J]．中国药物警戒，2013,10(3):163-165．
• [29]Committee for Medicinal Products for Human Use.Assessment report as adopted by the PRAC and considered by the CMDh with all information of a commercially confidential nature deleted:Ambroxol and bromhexine containing medicinal products[R].Europe:European Medicines Agency,2015．
• [30]邢丽娟．雾化吸入盐酸氨溴索过敏1例报告[J]．山东医药，2010,50(18):16．
• [31]时海洋．雾化吸入氨溴索在慢性阻塞性肺疾病急性加重期治疗中的作用与安全性评价[D]．济南:山东大学，2015．
• [32]黄秋明，唐燃原，袁永建．盐酸氨溴索注射液的配伍禁忌与机制分析[J]．中国药业，2011,20(18):48-49．
• [33]李玲，高雁，葛泉丽，等．盐酸氨溴索注射液不良反应研究综述[J]．广州化工，2015,43(14):33-34．
• [34]Qaseem A,Snow V,Fitterman N,et al.Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery:a guideline from the American College of Physicians[J].Ann Intern Med,2006,144(8):575-580.